UNLIMITED TURBO SHORT - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:01 2024-06-04 EDT | ||
| 2.67 EUR | -8.25% |
|
| Current month | -9.18% | ||
| 1 month | -32.06% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 2.67 | -8.25% |
| 24-06-03 | 2.91 | -1.02% |
| 24-05-31 | 2.94 | -2.33% |
| 24-05-30 | 3.01 | -1.95% |
| 24-05-29 | 3.07 | +1.99% |
Real-time Euronext Paris
Last update June 04, 2024 at 12:30 pm
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| TS4NB | |
| ISIN | NLBNPNL2O292 |
| Date issued | 2024-02-26 |
| Strike | 1,120 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.67 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.465 € |
|---|---|
| Lowest since issue | 2.62 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Certificates
- TS4NB Certificat
